ABT · 8-K · 20260820PR099247

Infant Formula Litigation

ABBOTT LABORATORIES · 2026-08-20 · Importance 56 · Surprise 58

Abbott agreed with three law firms to resolve the Gill case and claims involving approximately 2,000 additional individuals concerning specialty formulas for preterm infants. The aggregate settlement is approximately $670 million, compared with roughly $600 million for the Gill judgment and accrued interest alone. The agreements resolve disputed claims without admitting liability. After the agreements, approximately 1,700 lawsuits remain pending in federal and state courts involving claims on behalf of approximately 12,700 individual infants.

Key facts

• Abbott has reached agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals relating to the company’s specialty formulas for preterm infants. source
• The press release states that Abbott believes the agreements are in its best long-term interest and represent a constructive step toward substantially resolving the overall litigation. source
• Following these agreements, there are roughly 1,700 lawsuits pending in federal and state courts involving claims on behalf of approximately 12,700 individual infants. source
• That population of claims includes individuals who named both Abbott and Mead Johnson without identifying which manufacturer's formula was administered, individuals diagnosed with NEC before receiving any formula, individuals who were never diagnosed with NEC, and individuals who appear in multiple lawsuits in different jurisdictions. source
• Abbott continues to work to identify and eliminate such claims and others like them. source
• These agreements are a compromise of disputed claims and not in any way an admission of liability. source